Effect of Ginkgolide in Ischemic Stroke patients with large Artery Atherosclerosis: Results from a randomized trial.

Qiang DongJingyu ZhangYanxia WangLihong ZhaoRunhui LiChunhua WeiQingke BaiLishu WanLiping SunShejun FengMingyao YouChun WangHongtian ZhangQing HeMing YuQiang Dongnull null

Published in: CNS neuroscience & therapeutics (2021)

Ginkgolide, working as PAF antagonist, may reduce recurrent stroke in AIS with ICAS patients within 72 hours after onset. It might be an optional treatment in moderate-to-severe AIS patients with ICAS. (http://www.chictr.org.cn Number as ChiCTR-IPR-17012310).

Keyphrases

end stage renal disease
atrial fibrillation
ejection fraction
newly diagnosed
cardiovascular disease
prognostic factors
peritoneal dialysis
squamous cell carcinoma
lymph node metastasis
high intensity
patient reported